Author

Maximilian Werner

German Cancer Research CenterORCID 0000-0003-0252-5057Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Christoph E. HeiligiD· 2 shared Hanno GlimmiD· 2 shared Olaf WittiD· 2 shared Peter HorakiD· 2 shared Simon KreutzfeldtiD· 2 shared Stefan Froehling· 2 shared Vivek VenkataramaniiD· 2 shared Albrecht StenzingeriD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Christoph E. HeiligORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJul 9, 2026

Prospective pan-cancer phosphoproteomics at clinical scale extends therapeutic options in precision oncology

Annika Schneider, Julia Wortmann, Cecilia Bang Jensen…·Bernhard Küster

This study uses pan-cancer phosphoproteomics to identify therapeutic targets and improve precision oncology by analyzing 1,998 tumor samples and developing new scores for kinase activity and immune response.

DOI 10.64898/2026.07.08.737171

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintFeb 19, 2026

Systematic functional drug testing in patient-derived models reveals ex vivo sensitivities associated with clinical outcome in rare solid tumors

Jasmina Paluncic, Zunamys Itzell Carrero, Lilly KS Fischer…·Claudia R. Ball

This study develops an ex vivo drug sensitivity testing platform for rare solid tumors and finds that high in vitro sensitivity correlates with clinical benefit and progression-free survival.

1 citation

humanexperimental assay

𝕏 PostBluesky